Norway pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Practice Dispatch
Canada pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The pharmacy regulator in Canada has issued counselling standards for initiation of GLP-1 receptor agonist therapy, specifying what must be covered at the point of supply: device technique, expected adverse effects, what to do about a missed dose, storage, sharps disposal, and — notably — what happens if treatment stops.
The titration document sets out three permissible responses to unresolved symptoms at a given dose: hold at the current dose for a further interval, return to the previous dose, or discontinue. It declines to specify a maximum hold duration, on the stated grounds that no evidence supports one.
The evidence base for most practical questions in this field is thin, and the better guidance documents say so explicitly rather than manufacturing a recommendation grade. The Journal reports the stated evidence quality alongside the recommendation, because a strong recommendation on low-quality evidence is a different object from a strong recommendation on high-quality evidence.
Grete Skarsvåg, pharmacoeconomist, Norwegian Institute of Public Health, noted who the document does not reach. "None of my patients who buy online will ever see this. That population is entirely outside the guidance system."
We have asked the issuing body whether the guidance will be reviewed on a fixed cycle and what would trigger an earlier revision.
Related coverage
Target dose, effective dose, and the distance between them
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.
The restart nobody plans for
We work through the residual-exposure table so the decision can be made from numbers rather than from feel.
The dose that got you here and the dose that keeps you here
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Why your laboratory interval differs from the one in the textbook
Two sources of noise sit under every number: how reproducible the assay is, and how much the analyte varies within the same person on the same day.
What the placebo arms of the withdrawal trials actually tell us
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.